摘要
目的:观察参松养心胶囊治疗功能性早搏的临床疗效和安全性。方法:选择无器质性心脏病的早搏患者76例,随机分成参松养心胶囊治疗组和美托洛尔对照组,每组38例。给予治疗组每次口服参松养心胶囊4粒,每天3次;对照组每次口服美托洛尔片25mg,每天2次。以4周为1个疗程,观察用药前后心率、临床症状、早搏次数及不良反应情况。结果:4周后治疗组显效13例,有效20例,总有效率86.8%。对照组显效11例,有效21例,总有效率84.2%,两组比较无显著性差异(P>0.05)。在血压、心率波动方面参松养心胶囊明显优于美托洛尔。结论:参松养心胶囊治疗功能性早搏疗效与美托洛尔相似,且不良反应少,值得临床推广应用。
Objective： To observe the clinical curative effect and safety of Shensongyangxin capsule in the treatment of functional premature beat（FPB）. Methods： 76 patients with FPB were randomly divided into two groups： treatment group（n=38） was given Shensongyangxin capsule（4 capsules, three times a day ） and control group was given metoprolol（25mg twice a day） respectxvely, one course ot trea^men~ was tour wce~. To observe heart rate, clinical symptoms , the number of premature and adverse reactions before and after treatment. Results： After four weeks, the total effective rate was 86.8% in treatment group （with the 13 excellence and 20 efficiency） ;while that in control group was 84.2% （with the 11 excellence and 21 efficiency）. There was no significant difference between the two groups（P〉0. 05）. In blood pressure and heart rate fluctuations, Shensongyangxin capsule is better than metoprolol. Conclusion： Shensongyangxin capsule was similar to metoprolol in the treatment of FPB, and the untoward effect are few. Ifs well worth to spreading in the clinical application.
出处
《数理医药学杂志》
2009年第1期32-34,共3页
Journal of Mathematical Medicine
关键词
参松养心胶囊
功能性早搏
疗效
shensongyangxin capsule
functional premature beat
curative effect
